b|e|i RESOURCES

SUPPORTING INFECTIOUS DISEASE RESEARCH

DATA SHEET

For research use only. Not for use in humans.

Reagent: H9 Cells

Catalog Number: ARP-87

Lot Number: 140405

Provided: Each vial of ARP-87 contains approximately 4.4 × 10^6 cells/mL. Post-thaw viability was 38%.

Cell Type: ARP-87, H9 cells, are a single cell clone derived from a specific HUT 78 cell line, HT. HUT 78 is a human cutaneous T cell lymphoma derived from the peripheral blood of a patient with Sezary syndrome.

Propagation Medium: The recommended propagation medium is RPMI-1640 supplemented with 2 mM L-glutamine, 50 µg/mL gentamicin and 10% fetal bovine serum (FBS).

Freeze Medium: The recommended freeze medium is RPMI-1640, 80%; FBS, 10%; DMSO, 10%.

Growth Characteristics: Maintain ARP-87 cells at 1 × 10^5 to 1 × 10^6 cells/mL. H9 grows as a single cell suspension with some clumping. Cells should be split 1:2 to 1:4 weekly. Morphology is mature lymphocytic.

Sterility: Tests for bacteria, fungi and mycoplasma were negative.

Special Characteristics: ARP-87 was selected for high-yield permissive growth with HIV-1.

Recommended Storage: Keep at -100°C or colder, preferably in the vapor phase of a liquid nitrogen freezer.

Contributor: Dr. Robert Gallo

References:

Mann, D. L., et al. "Origin of the HIV-Susceptible Human $CD4^+$ Cell Line H9." AIDS Hum. Res. Retroviruses 5 (1989): 253-255. PubMed: 2567177.

Popovic, M., E. Read-Connole and R. C. Gallo. "T4 Positive Human Neoplastic Cell Lines Susceptible to and Permissive for HTLV-III." Lancet 2 (1984): 1472-1473. PubMed: 6151082.

Popovic, M., et al. "Detection, Isolation and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDS." 224 Science (1984): 495-500. PubMed: 6200935.

Citation: Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: H9 Cells, ARP-87."

Biosafety Level: 1 Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers: You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

Note:

The use of the H9 cell line and other neoplastic T cell lines to produce HIV-1 is described in U.S. Patent 4,520,113.

ATCC® is a trademark of the American Type Culture Collection.

HIV REAGENT PROGRAM Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898